# Beijing Wujiahe Gene Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-wujiahe-gene-technology-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.fiveplusgene.com.cn
- Latest round: Series A (Sep 28, 2021)
- Investors on record: 4

## About

Based in China, established in 2018, Beijing Wujiahe Gene Technology Co., Ltd is a gene therapy medicine R&D and its related services company that focuses on research and developing virus vector. It was founded by its parent company, Beijing Fiveplus Molecular Medicine Institute. Its core  technical team come from parent company, who has over 20 years experience of gene therapy virus vector research and was involved in a number of nation-level project, and also joined the draft of Quality standard of Natioanl AAV vector gene medicine. It has over 2600 square meters of experiment area and a 600 square meters GMP level pilot test area, 1000 square meters of R&D lab.

The company offers an one-stop contract development manufacture organization (CDMO) service from molecular design, process exploration to clinical test medicine manufacturing and quality evaluation. It provided herpes simplex virus(HSV)manufacturing to client and has already been approved for clinical trail by NMPA in Jul, 2019.

## Funding rounds

- Series A, Sep 28, 2021 — HJ Investment, Hangzhou Aopeng Investment Management
- Angel, Nov 22, 2019 — Beishang Capital, Beijing Wujiahe Molecule Medical Institute Co.,Ltd.

## Investors

- Beishang Capital (https://capitalatlas.ai/funds/beishang-capital) — Angel
- Beijing Wujiahe Molecule Medical Institute Co.,Ltd. — Angel
- HJ Investment (https://capitalatlas.ai/funds/hj-investment) — Series A
- Hangzhou Aopeng Investment Management (https://capitalatlas.ai/funds/hangzhou-aopeng-investment-management) — Series A